FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282913561> ?p ?o ?g. }

• W4282913561 endingPage "e958" @default.
• W4282913561 startingPage "e958" @default.
• W4282913561 abstract "Authors' reply We fully agree with Gabriele Rossi that the evaluation of simplified protocols aimed at optimising the management of uncomplicated acute malnutrition in children should include analyses dedicated to the most clinically vulnerable children. This is exactly the reason why the OptiMA-DRC trial was done in two stages. Beyond the evaluation already reported1Cazes C Phelan K Hubert V et al.Simplifying and optimising the management of uncomplicated acute malnutrition in children aged 6–59 months in the Democratic Republic of the Congo (OptiMA-DRC): a non-inferiority, randomised controlled trial.Lancet Glob Health. 2022; 10: e510-e520Summary Full Text Full Text PDF PubMed Scopus (3) Google Scholar in the entire population of children presenting with acute malnutrition, defined as a mid-upper-arm circumference (MUAC) of less than 125 mm, a weight-for-height Z score (WHZ) of less than –3, or oedema, we then continued to enrol children with a MUAC of less than 115 mm, a WHZ of less than –3, or an oedema at baseline, so that we had enough statistical power to compare across study groups the proportion of children who met the WHO definition of severe acute malnutrition2WHO and UNICEFWHO child growth standards and the identification of severe acute malnutrition in infants and children: a joint statement by the World Health Organization and the United Nations Children's Fund. World Health Organization, Geneva2009Google Scholar who recovered. This evaluation among children with severe acute malnutrition is reported elsewhere3Cazes C Phelan K Hubert V et al.Optimising the dosage of ready-to-use therapeutic food in children with uncomplicated severe acute malnutrition: a non-inferiority randomised controlled trial in the Democratic Republic of Congo.SSRN. 2022; (published online May 13.) (preprint).https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4099994Crossref Google Scholar and showed that the proportion of children in the trial who recovered during the 6-month follow-up was non-inferior in the OptiMA group (96% in OptiMA group vs 98% in the standard group; difference 2·0%, 95% CI–2·0 to 6·4). There was severe stunting (ie, height-for-age Z [HAZ] score <–3) among children presenting with acute malnutrition in 45% of children in the standard treatment group and in 40% of children in the OptiMA group at baseline and the difference between groups was not statistically significant (p=0·1620). We used logistic regression analysis to further investigate whether a HAZ of less than –3 at baseline was associated with the primary endpoint of a favourable outcome at 6 months and there was no association, even after adjustment for potential confounders. At 6 months after randomisation, the proportion of children with severe stunting was 71% in the standard treatment group and 65% in the OptiMA group (p=0·057). Our hypothesis to explain this almost statistically significant difference is that 71% of children in the standard treatment group received a nutritional treatment, whereas 100% of the children in the OptiMA group received such treatment. This difference contributed to further deterioration in the nutritional status of children in the standard treatment group. Our interpretation is that integrating severe and moderate acute malnutrition treatment into one programme, using one product, could lead to better nutritional status at 6 months after programme inclusion. We also agree that it is crucial to evaluate the OptiMA strategy among children presenting with a combination of wasting and stunting, who are at the greatest risk of short-term mortality.4Myatt M Khara T Schoenbuchner S et al.Children who are both wasted and stunted are also underweight and have a high risk of death: a descriptive epidemiology of multiple anthropometric deficits using data from 51 countries.Arch Public Health. 2018; 76: 28Crossref PubMed Scopus (67) Google Scholar A secondary analysis restricted to these most clinically vulnerable children is currently underway to investigate whether there was a difference in safety and recovery outcomes between study groups. KP serves on the Social Purposes Advisory Commission of Nutriset, a main producer of lipid-based nutrient supplement products. All other authors declare no competing interests. Simplifying and optimising the management of uncomplicated acute malnutrition in children aged 6–59 months in the Democratic Republic of the Congo (OptiMA-DRC): a non-inferiority, randomised controlled trialIn this non-inferiority trial treating children with MUAC of less than 125 mm or oedema, decreasing RUTF dose according to MUAC and weight increase proved to be a superior strategy to the standard protocol in the Democratic Republic of the Congo. These results demonstrate the safety and benefits of an approach that could substantially increase access to treatment for millions of children with acute malnutrition in sub-Saharan Africa. Full-Text PDF Open AccessThe OptiMA protocol in children with wasting and stuntingIn their open-label, non-inferiority, randomised controlled trial, Cécile Cazes and colleagues (April, 2022)1 assessed the efficacy, safety, and cost implications of a single protocol for moderate acute and severe acute malnutrition management, using only ready-to-use therapeutic food (RUTF) at a decreasing dose as weight and mid-upper-arm circumference (MUAC) increase (OptiMA strategy) in the Democratic Republic of the Congo. Full-Text PDF Open Access" @default.
• W4282913561 created "2022-06-16" @default.
• W4282913561 creator A5033064853 @default.
• W4282913561 creator A5039874457 @default.
• W4282913561 creator A5043036854 @default.
• W4282913561 creator A5067271629 @default.
• W4282913561 creator A5072892616 @default.
• W4282913561 date "2022-07-01" @default.
• W4282913561 modified "2023-09-30" @default.
• W4282913561 title "The OptiMA protocol in children with wasting and stunting – Authors' reply" @default.
• W4282913561 cites W2808643466 @default.
• W4282913561 cites W4229058127 @default.
• W4282913561 cites W4285185784 @default.
• W4282913561 doi "https://doi.org/10.1016/s2214-109x(22)00245-5" @default.
• W4282913561 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35714646" @default.
• W4282913561 hasPublicationYear "2022" @default.
• W4282913561 type Work @default.
• W4282913561 citedByCount "0" @default.
• W4282913561 crossrefType "journal-article" @default.
• W4282913561 hasAuthorship W4282913561A5033064853 @default.
• W4282913561 hasAuthorship W4282913561A5039874457 @default.
• W4282913561 hasAuthorship W4282913561A5043036854 @default.
• W4282913561 hasAuthorship W4282913561A5067271629 @default.
• W4282913561 hasAuthorship W4282913561A5072892616 @default.
• W4282913561 hasBestOaLocation W42829135611 @default.
• W4282913561 hasConcept C126322002 @default.
• W4282913561 hasConcept C187212893 @default.
• W4282913561 hasConcept C2776610293 @default.
• W4282913561 hasConcept C2779764123 @default.
• W4282913561 hasConcept C2908647359 @default.
• W4282913561 hasConcept C2909598931 @default.
• W4282913561 hasConcept C512399662 @default.
• W4282913561 hasConcept C551997983 @default.
• W4282913561 hasConcept C61427482 @default.
• W4282913561 hasConcept C71924100 @default.
• W4282913561 hasConcept C99454951 @default.
• W4282913561 hasConceptScore W4282913561C126322002 @default.
• W4282913561 hasConceptScore W4282913561C187212893 @default.
• W4282913561 hasConceptScore W4282913561C2776610293 @default.
• W4282913561 hasConceptScore W4282913561C2779764123 @default.
• W4282913561 hasConceptScore W4282913561C2908647359 @default.
• W4282913561 hasConceptScore W4282913561C2909598931 @default.
• W4282913561 hasConceptScore W4282913561C512399662 @default.
• W4282913561 hasConceptScore W4282913561C551997983 @default.
• W4282913561 hasConceptScore W4282913561C61427482 @default.
• W4282913561 hasConceptScore W4282913561C71924100 @default.
• W4282913561 hasConceptScore W4282913561C99454951 @default.
• W4282913561 hasIssue "7" @default.
• W4282913561 hasLocation W42829135611 @default.
• W4282913561 hasLocation W42829135612 @default.
• W4282913561 hasLocation W42829135613 @default.
• W4282913561 hasLocation W42829135614 @default.
• W4282913561 hasLocation W42829135615 @default.
• W4282913561 hasLocation W42829135616 @default.
• W4282913561 hasLocation W42829135617 @default.
• W4282913561 hasLocation W42829135618 @default.
• W4282913561 hasOpenAccess W4282913561 @default.
• W4282913561 hasPrimaryLocation W42829135611 @default.
• W4282913561 hasRelatedWork W1526394214 @default.
• W4282913561 hasRelatedWork W1568680685 @default.
• W4282913561 hasRelatedWork W182256127 @default.
• W4282913561 hasRelatedWork W2131745875 @default.
• W4282913561 hasRelatedWork W2138777526 @default.
• W4282913561 hasRelatedWork W2214808057 @default.
• W4282913561 hasRelatedWork W2888145184 @default.
• W4282913561 hasRelatedWork W3167058434 @default.
• W4282913561 hasRelatedWork W4212804165 @default.
• W4282913561 hasRelatedWork W1985064582 @default.
• W4282913561 hasVolume "10" @default.
• W4282913561 isParatext "false" @default.
• W4282913561 isRetracted "false" @default.
• W4282913561 workType "article" @default.